Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (Nature Medicine, (2023), 29, 2, (422-429), 10.1038/s41591-022-02182-7)

Sham Mailankody, Jeffrey V. Matous, Saurabh Chhabra, Michaela Liedtke, Surbhi Sidana, Olalekan O. Oluwole, Shahbaz Malik, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, Myo Htut, Erin E. Karski, Wade Lovelace, Myles Dillon, Eric Butz, Wendy Ying, Arun Balakumaran, Shaji K. Kumar

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (Nature Medicine, (2023), 29, 2, (422-429), 10.1038/s41591-022-02182-7)'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds